Cargando…
Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design
The observation of an infusion reaction (IR) in a nonclinical study can cause concern among investigators and regulators in the development of biotherapeutics. Biomarkers can be informative to determine whether the reactions are immune-mediated or test-article related and if there is a potential ris...
Autores principales: | Mease, Kirsten M., Kimzey, Amy L., Lansita, Janice A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893855/ https://www.ncbi.nlm.nih.gov/pubmed/29658009 http://dx.doi.org/10.1016/j.cotox.2017.03.005 |
Ejemplares similares
-
A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats
por: Sibley, Katherine, et al.
Publicado: (2019) -
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
por: Welsh, Brian T., et al.
Publicado: (2021) -
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
por: Moffit, Jeffrey S., et al.
Publicado: (2022) -
Intrinsic physicochemical profile of marketed antibody-based biotherapeutics
por: Ahmed, Lucky, et al.
Publicado: (2021) -
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
por: Fekete, Emily Ef, et al.
Publicado: (2023)